Program dla osób z MASH i włóknieniem wątroby
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis (ENLIGHTEN)
Obszar terapeutyczny
Hepatologia
Program ENLIGHTEN-Cirrhosis dla osób z marskością wątroby
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH (ENLIGHTEN-Cirrhosis)
Program dla osób z MASH/NASH i włóknieniem wątroby
A randomized, double-blind, placebo-controlled, multicentre Phase 3 trial evaluating long-term efficacy and safety of weekly survodutide injections in adults with MASH/NASH and F2–F3 liver fibrosis
Program dla osób z marskością wątroby w przebiegu MASH/NASH
A Phase 3 double-blind, randomized, placebo-controlled trial evaluating liver-related clinical outcomes and safety of once-weekly survodutide in participants with compensated MASH/NASH cirrhosis
Program SYNERGY-Outcomes dla osób z MASLD
SYNERGY-Outcomes – A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adults With MASLD at Increased Risk of Major Adverse Liver Outcomes
Program ZENITH-1 dla osób z MASH potwierdzonym biopsją
ZENITH-1 – A Phase 3 study of efimosfermin alfa in participants with biopsy-confirmed F2- or F3-stage MASH
Program ZENITH-2 dla osób z rozpoznanym lub podejrzewanym MASH
ZENITH-2 – A Phase 3 study to investigate the safety and tolerability of efimosfermin alfa in participants with known or suspected F2- or F3-stage MASH